瑞德西韦与急性肾衰竭:WHO安全数据库的不比例性分析安全信号
基于WHO国际药物警戒数据库VigiBase,采用不比例性分析方法评估瑞德西韦与急性肾衰竭的关联。报告比值比(ROR)显示瑞德西韦相关急性肾衰竭报告呈统计学显著信号,观察138例而预期9例,ROR为20.3(95%CI 15.7-26.3,P<0.0001)。提示需对COVID-19患者用药前后评估肾功能。
要点
- VigiBase不比例性分析发现瑞德西韦与急性肾衰竭存在统计学显著信号。
- 急性肾衰竭观察138例,预期9例,ROR 20.3(95%CI 15.7-26.3,P<0.0001)。
- COVID-19患者使用瑞德西韦前及治疗期间应评估肾功能。
核心结论
- 基于VigiBase数据检测到瑞德西韦相关肾毒性的统计学显著药物警戒信号,值得对全部可用数据进行深入定性评估。
研究设计与样本
- 对WHO国际药物警戒上市后数据库VigiBase进行不比例性分析,采用两种不比例性方法。
主要发现
- 「急性肾衰竭」与「瑞德西韦」组合产生统计学显著不比例性信号,观察138例而预期9例。
- 瑞德西韦相关急性肾衰竭的ROR为20.3(95%CI 15.7-26.3,P<0.0001),约为对照药物的20倍。
关键数值与推荐
- ROR比较瑞德西韦与COVID-19可比情境下其他药物(羟氯喹、托珠单抗、洛匹那韦/利托那韦)报告的急性肾衰竭病例数。
- 瑞德西韦急性肾衰竭ROR为20.3(95%CI 15.7-26.3,P<0.0001)。
临床怎么用
- 如产品特性摘要所推荐,COVID-19患者在使用瑞德西韦前及治疗期间应优先评估肾功能。
局限性
- 研究结果受COVID-19疫情背景固有局限性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) and authorized conditionally by the European Medicines Agency (EMA) for patients with coronavirus disease 2019 (COVID-19). Its benefit-risk ratio is still being explored because data in the field are rather scant. A decrease of the creatinine clearance associated with remdesivir has been inconstantly reported in clinical trials with unclear relevance. Despite these uncertainties, we searched for a potential signal of acute renal failure (ARF) in pharmacovigilance postmarketing data. An analysis of the international pharmacovigilance postmarketing databases (VigiBase) of the World Health Organization (WHO) was performed, using two disproportionality methods. Reporting odds ratio (ROR) compared the number of ARF cases reported with remdesivir, with those reported with other drugs prescribed in comparable situations of COVID-19 (hydroxychloroquine, tocilizumab, and lopinavir/ritonavir). The combination of the terms "acute renal failure" and "remdesivir" yielded a statistically significant disproportionality signal with 138 observed cases instead of the 9 expected. ROR of ARF with remdesivir was 20-fold (20.3; confidence interval 0.95 [15.7-26.3], P < 0.0001]) that of comparative drugs. Based on ARF cases reported in VigiBase, and despite the caveats inherent to COVID-19 circumstances, we detected a statistically significant pharmacovigilance signal of nephrotoxicity associated with remdesivir, deserving a thorough qualitative assessment of all available data. Meanwhile, as recommended in its Summary of Product Characteristics, assessment of patients with COVID-19 renal function should prevail before and during treatment with remdesivir in COVID-19.
引用
- Gérard AO, Laurain A, Fresse A, et al. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database. Clin Pharmacol Ther. 2021. PMID: 33340409. doi:10.1002/cpt.2145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。